KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial.Acta Derm VenereolPMID 38436429PMC109242692024-Mar-040.98未发现恶性肿瘤人群证据。待处理
Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate.JAMA Netw OpenPMID 38488793PMC109434142024-Mar-040.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.LancetPMID 38387470无 PMCID2024-Mar-020.98未发现恶性肿瘤人群证据。待处理
Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis.Int Clin PsychopharmacolPMID 37551609PMC108331862024-Mar-010.98未发现恶性肿瘤人群证据。待处理
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.Am J GastroenterolPMID 37561058PMC109039972024-Mar-010.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.HaematologicaPMID 37646660PMC109050852024-Mar-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-Term Results From the PKUFH Randomized Phase 3 Trial.Int J Radiat Oncol Biol PhysPMID 37717784无 PMCID2024-Mar-010.85The study is an eligible Phase III randomized oncology trial with time-to-event endpoints, but the intervention is radiation therapy alone, not a drug-containing intervention as required by the adjudication criteria.待处理
Racecadotril Versus Loperamide in Acute Radiation Enteritis: A Randomized, Double-Masked, Phase 3, Noninferiority Trial.Int J Radiat Oncol Biol PhysPMID 37742773无 PMCID2024-Mar-010.95The trial meets criteria for being a human, oncology-context, Phase III randomized trial with a drug intervention and is an original result. However, it is excluded because the primary efficacy endpoint is not a time-to-event endpoint (e.g., OS, PFS, DFS) or a Kaplan-Meier/HR analysis; it is a categorical response rate at a fixed time point.待处理
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.J Crohns ColitisPMID 37797293PMC109069492024-Mar-010.98未发现恶性肿瘤人群证据。待处理
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.J Clin OncolPMID 38042525PMC109065632024-Mar-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.J Travel MedPMID 38091981PMC109110602024-Mar-010.98未发现恶性肿瘤人群证据。待处理
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.JAMA OncolPMID 38127362PMC107390772024-Mar-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.J Clin OncolPMID 38194625PMC109066382024-Mar-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.JAMA OncolPMID 38236590PMC107975212024-Mar-010.95The trial is ineligible because it lacks a primary or key secondary time-to-event efficacy endpoint. All specified criteria for inclusion require a TTE endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier analysis, which are absent from this report.待处理
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.J Am Soc NephrolPMID 38261535PMC109141882024-Mar-010.98未发现恶性肿瘤人群证据。待处理
Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.JAMA PediatrPMID 38315470PMC108450382024-Mar-010.98未发现恶性肿瘤人群证据。待处理
Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel.J Drugs DermatolPMID 38443130无 PMCID2024-Mar-010.98未发现恶性肿瘤人群证据。待处理
Comparing Impact of Overactive Bladder Therapies on Nocturia.Urogynecology (Phila)PMID 38484241无 PMCID2024-Mar-010.98未发现恶性肿瘤人群证据。待处理
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.Eur UrolPMID 37778952无 PMCID2024-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The Orphan Drug for Acanthamoeba Keratitis (ODAK) Trial: PHMB 0.08% (Polihexanide) and Placebo versus PHMB 0.02% and Propamidine 0.1.OphthalmologyPMID 37802392无 PMCID2024-Mar0.98未发现恶性肿瘤人群证据。待处理
START NOW: a cognitive behavioral skills training for adolescent girls with conduct or oppositional defiant disorder - a randomized clinical trial.J Child Psychol PsychiatryPMID 37814906无 PMCID2024-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.J Am Acad DermatolPMID 37852306无 PMCID2024-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.Lancet Infect DisPMID 38008099无 PMCID2024-Mar0.98未发现恶性肿瘤人群证据。待处理
The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.Clin Pharmacol TherPMID 38012534无 PMCID2024-Mar0.98未发现恶性肿瘤人群证据。待处理
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.Ann OncolPMID 38048850无 PMCID2024-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.LeukemiaPMID 38062124PMC109120322024-Mar0.45The study is a secondary analysis of pooled Phase III trials in multiple myeloma, focusing on morbidity and mortality during induction therapy. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or hazard ratio data.待处理
A Randomized Phase III Trial of Complete Mesocolic Excision Compared with Conventional Surgery for Right Colon Cancer: Interim Analysis of a Nationwide Multicenter Study of the Italian Society of Surgical Oncology Colorectal Cancer Network (CoME-in trial).Ann Surg OncolPMID 38087139PMC108382392024-Mar0.93干预为非药物单独策略,未满足药物干预要求。待处理
Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.Lancet Infect DisPMID 38109921PMC108814052024-Mar0.98未发现恶性肿瘤人群证据。待处理
Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.J Allergy Clin Immunol PractPMID 38122865无 PMCID2024-Mar0.98未发现恶性肿瘤人群证据。待处理
Pharmacotherapy for the Prevention of Depression and Behavioral Side Effects in Hematopoietic Stem Cell Transplantation Patients.Transplant Cell TherPMID 38147899无 PMCID2024-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.Adv TherPMID 38183525PMC108792252024-Mar0.98未发现恶性肿瘤人群证据。待处理
Co-crystal of Tramadol-Celecoxib Versus Tramadol or Placebo for Acute Moderate-to-Severe Pain After Oral Surgery: Randomized, Double-Blind, Phase 3 Trial (STARDOM1).Adv TherPMID 38183526PMC108793712024-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.Adv TherPMID 38194047PMC108792302024-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.Lancet Gastroenterol HepatolPMID 38211604无 PMCID2024-Mar0.98未发现恶性肿瘤人群证据。待处理
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.Paediatr DrugsPMID 38267692PMC108909782024-Mar0.98未发现恶性肿瘤人群证据。待处理
Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study.Respir InvestigPMID 38277865无 PMCID2024-Mar0.98未发现恶性肿瘤人群证据。待处理
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.Gastric CancerPMID 38281295PMC108968032024-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.Clin Drug InvestigPMID 38300386无 PMCID2024-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study.Nat MedPMID 38302715无 PMCID2024-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.Eur J CancerPMID 38309017无 PMCID2024-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial.J Clin Hypertens (Greenwich)PMID 38319595PMC109187102024-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.Lancet Diabetes EndocrinolPMID 38330988无 PMCID2024-Mar0.98未发现恶性肿瘤人群证据。待处理
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.Lung CancerPMID 38354535无 PMCID2024-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Anxiety-focused cognitive behavioral therapy delivered by non-specialists to prevent postnatal depression: a randomized, phase 3 trial.Nat MedPMID 38365951PMC110608452024-Mar0.98未发现恶性肿瘤人群证据。待处理
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.Lancet HaematolPMID 38423700无 PMCID2024-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.Target OncolPMID 38427280PMC109634342024-Mar0.90The record describes a single-arm Phase II trial. While it is an oncology study on human patients and reports a time-to-event outcome (PFS), it is excluded because it is not a randomized controlled trial and is only a Phase II study, not a Phase III or otherwise definitive randomized trial as required.待处理
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.Lancet Healthy LongevPMID 38432247无 PMCID2024-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial.ESMO OpenPMID 38471240PMC109440992024-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
The feasibility and acceptability of an app-based intervention with brief behavioural support (APPROACH) to promote brisk walking in people diagnosed with breast, prostate and colorectal cancer in the UK.Cancer MedPMID 38529687PMC109641762024-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.N Engl J MedPMID 37962077无 PMCID2024-Feb-290.98未发现恶性肿瘤人群证据。待处理